XML 21 R8.htm IDEA: XBRL DOCUMENT
v3.20.2

Revenue (Notes) | 9 Months Ended
--- | ---
Oct. 02, 2020
Revenue from Contract with Customer [Abstract] |
Revenue | REVENUE The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three and nine-month periods ended October 2, 2020 and September 27, 2019 ($ in millions). Sales taxes and other usage-based taxes collected from customers are excluded from revenue.
| Life Sciences |  | Diagnostics |  | Environmental & Applied Solutions |  | Total
For the Three-Month Period Ended October 2, 2020: |  |  |  |  |  |  |
Geographical region: |  |  |  |  |  |  |
North America | $ | 1,100.6 |  |  | $ | 797.8 |  |  | $ | 481.0 |  |  | $ | 2,379.4 |
Western Europe | 779.7 |  |  | 349.2 |  |  | 245.1 |  |  | 1,374.0 |
Other developed markets | 193.4 |  |  | 103.6 |  |  | 29.2 |  |  | 326.2 |
High-growth markets (a) | 848.8 |  |  | 638.5 |  |  | 316.3 |  |  | 1,803.6 |
Total | $ | 2,922.5 |  |  | $ | 1,889.1 |  |  | $ | 1,071.6 |  |  | $ | 5,883.2 |
Revenue type: |  |  |  |  |  |  |
Recurring | $ | 2,075.5 |  |  | $ | 1,541.6 |  |  | $ | 609.9 |  |  | $ | 4,227.0 |
Nonrecurring | 847.0 |  |  | 347.5 |  |  | 461.7 |  |  | 1,656.2 |
Total | $ | 2,922.5 |  |  | $ | 1,889.1 |  |  | $ | 1,071.6 |  |  | $ | 5,883.2 |
For the Three-Month Period Ended September 27, 2019: |  |  |  |  |  |  |
Geographical region: |  |  |  |  |  |  |
North America | $ | 637.2 |  |  | $ | 602.9 |  |  | $ | 465.5 |  |  | $ | 1,705.6 |
Western Europe | 444.1 |  |  | 257.9 |  |  | 252.8 |  |  | 954.8 |
Other developed markets | 149.2 |  |  | 108.4 |  |  | 32.5 |  |  | 290.1 |
High-growth markets (a) | 465.1 |  |  | 632.7 |  |  | 329.7 |  |  | 1,427.5 |
Total | $ | 1,695.6 |  |  | $ | 1,601.9 |  |  | $ | 1,080.5 |  |  | $ | 4,378.0 |
Revenue type: |  |  |  |  |  |  |
Recurring | $ | 1,084.3 |  |  | $ | 1,343.2 |  |  | $ | 595.2 |  |  | $ | 3,022.7 |
Nonrecurring | 611.3 |  |  | 258.7 |  |  | 485.3 |  |  | 1,355.3 |
Total | $ | 1,695.6 |  |  | $ | 1,601.9 |  |  | $ | 1,080.5 |  |  | $ | 4,378.0 |
| Life Sciences |  | Diagnostics |  | Environmental & Applied Solutions |  | Total
For the Nine-Month Period Ended October 2, 2020: |  |  |  |  |  |  |
Geographical region: |  |  |  |  |  |  |
North America | $ | 2,721.1 |  |  | $ | 2,243.5 |  |  | $ | 1,430.1 |  |  | $ | 6,394.7 |
Western Europe | 1,962.9 |  |  | 974.3 |  |  | 720.4 |  |  | 3,657.6 |
Other developed markets | 524.4 |  |  | 297.9 |  |  | 88.4 |  |  | 910.7 |
High-growth markets (a) | 2,006.9 |  |  | 1,660.6 |  |  | 893.2 |  |  | 4,560.7 |
Total | $ | 7,215.3 |  |  | $ | 5,176.3 |  |  | $ | 3,132.1 |  |  | $ | 15,523.7 |
Revenue type: |  |  |  |  |  |  |
Recurring | $ | 5,135.0 |  |  | $ | 4,305.0 |  |  | $ | 1,809.3 |  |  | $ | 11,249.3 |
Nonrecurring | 2,080.3 |  |  | 871.3 |  |  | 1,322.8 |  |  | 4,274.4 |
Total | $ | 7,215.3 |  |  | $ | 5,176.3 |  |  | $ | 3,132.1 |  |  | $ | 15,523.7 |
For the Nine-Month Period Ended September 27, 2019: |  |  |  |  |  |  |
Geographical region: |  |  |  |  |  |  |
North America | $ | 1,878.1 |  |  | $ | 1,836.3 |  |  | $ | 1,403.0 |  |  | $ | 5,117.4 |
Western Europe | 1,363.7 |  |  | 828.5 |  |  | 774.1 |  |  | 2,966.3 |
Other developed markets | 436.1 |  |  | 295.6 |  |  | 92.7 |  |  | 824.4 |
High-growth markets (a) | 1,357.2 |  |  | 1,796.6 |  |  | 980.8 |  |  | 4,134.6 |
Total | $ | 5,035.1 |  |  | $ | 4,757.0 |  |  | $ | 3,250.6 |  |  | $ | 13,042.7 |
Revenue type: |  |  |  |  |  |  |
Recurring | $ | 3,264.4 |  |  | $ | 4,047.9 |  |  | $ | 1,770.2 |  |  | $ | 9,082.5 |
Nonrecurring | 1,770.7 |  |  | 709.1 |  |  | 1,480.4 |  |  | 3,960.2 |
Total | $ | 5,035.1 |  |  | $ | 4,757.0 |  |  | $ | 3,250.6 |  |  | $ | 13,042.7 |
(a) The Company defines high-growth markets as developing markets of the world experiencing extended periods of accelerated growth in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America and Asia (with the exception of Japan, Australia and New Zealand). The Company defines developed markets as all markets that are not high-growth markets. The Company sells equipment to customers as well as consumables, software licenses and services, some of which customers purchase on a recurring basis. Consumables sold for use with the equipment sold by the Company are typically critical to the use of the equipment and are typically used on a one-time or limited basis, requiring frequent replacement in the customer’s operating cycle. Examples of these consumables include reagents used in diagnostic tests, filters used in filtration, separation and purification processes and cartridges for marking and coding equipment. Additionally, some of the Company’s consumables are used on a standalone basis, such as water treatment solutions. The Company separates its goods and services between those sold on a recurring basis and those sold on a nonrecurring basis. Recurring revenue includes revenue from consumables, services, software licenses recognized over time, software-as-a-service licenses, sales-and-usage based royalties and operating-type leases (“OTLs”). Nonrecurring revenue includes sales from equipment, software licenses recognized at a point in time and sales-type leases (“STLs”). OTLs and STLs are included in the above revenue amounts. For the three-month periods ended October 2, 2020 and September 27, 2019, lease revenue was $112 million and $108 million, respectively. For the nine-month periods ended October 2, 2020 and September 27, 2019, lease revenue was $332 million and $320 million, respectively. Remaining performance obligations related to Topic 606, Revenue from Contracts with Customers, represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year which are fully or partially unsatisfied at the end of the period. As of October 2, 2020, the aggregate amount of the transaction price allocated to remaining performance obligations was approximately $2.8 billion. The Company expects to recognize revenue on approximately 51% of the remaining performance obligations over the next 12 months, 22% over the subsequent 12 months, and the remainder recognized thereafter. The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (“contract assets”) and deferred revenue, customer deposits and billings in excess of revenue recognized (“contract liabilities”) on the Consolidated Condensed Balance Sheets. Most of the Company’s long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in billing occurring subsequent to revenue recognition resulting in contract assets. Contract assets are generally classified as other current assets in the Consolidated Condensed Balance Sheets. The balance of contract assets as of October 2, 2020 and December 31, 2019 was $67 million and $77 million, respectively. The Company often receives cash payments from customers in advance of the Company’s performance resulting in contract liabilities. These contract liabilities are classified as either current or long-term in the Consolidated Condensed Balance Sheets based on the timing of when the Company expects to recognize revenue. As of October 2, 2020 and December 31, 2019, contract liabilities were approximately $1.3 billion and $806 million, respectively, and are included within accrued expenses and other liabilities and other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. The increase in the contract liability balance during the nine-month period ended October 2, 2020 was primarily a result of the Cytiva Acquisition (as defined below) and cash payments received in advance of satisfying performance obligations, partially offset by revenue recognized during the year that was included in the opening contract liability balance. Revenue recognized during the nine-month periods ended October 2, 2020 and September 27, 2019 that was included in the contract liability balance on December 31, 2019 and December 31, 2018 was $537 million and $497 million, respectively. Contract assets and liabilities are reported on the accompanying Consolidated Condensed Balance Sheets on a contract-by-contract basis.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration